Grufity logoGrufity logo

Ocular Therapeutix Inc Stock Research

OCUL

3.88USD-0.01(-0.26%)Market Closed

Market Summary

USD3.88-0.01
Market Closed
-0.26%

OCUL Stock Price

OCUL RSI Chart

OCUL Valuation

Market Cap

298.8M

Price/Earnings (Trailing)

-5.03

Price/Sales (Trailing)

6.01

Price/Free Cashflow

-4.98

OCUL Price/Sales (Trailing)

OCUL Profitability

Return on Equity

-128.37%

Return on Assets

-37.42%

Free Cashflow Yield

-20.08%

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

49.7M

Revenue Y/Y

-1.55%

Revenue Q/Q

-2.45%

OCUL Earnings

Earnings (TTM)

-59.3M

Earnings Y/Y

-1.0K%

Earnings Q/Q

-28.89%

Price Action

52 Week Range

2.576.53
(Low)(High)

Last 7 days

-5.4%

Last 30 days

47.0%

Last 90 days

5.4%

Trailing 12 Months

-25.9%

OCUL Financial Health

Current Ratio

4.98

OCUL Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-1.01

Peers (Alternatives to Ocular Therapeutix)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
442.1B
96.0B
-4.77% 1.21%
23.08
4.6
5.02% 7.14%
308.1B
29.2B
-6.33% 46.49%
51.07
10.54
5.34% 1.02%
267.0B
59.0B
-5.13% 34.98%
17.49
4.53
27.84% 112.03%
245.5B
99.9B
-13.80% -15.92%
8.25
2.46
45.01% 53.21%
154.0B
46.7B
0.64% 15.96%
23.07
3.3
2.79% 223.53%
MID-CAP
5.0B
4.4B
10.03% -0.57%
-46.66
1.14
1.80% 57.67%
2.2B
659.0M
13.79% 40.18%
57.51
3.29
16.78% -53.92%
SMALL-CAP
1.9B
613.6M
24.42% -38.51%
-3.79
3.14
37.73% -7.19%
1.6B
3.1M
23.90% 79.89%
-5.08
503.44
-77.09% -12.24%
1.4B
-
33.79% -57.23%
-0.46
1.95
-4.11% -144.36%
1.2B
23.5M
12.85% 73.07%
-14.2
49.6
243.57% -1.04%
942.1M
112.7M
- -24.55%
-4.21
8.36
45.53% 40.26%
885.5M
-
-2.61% -19.99%
2.65
2.34
10.49% -16.07%
298.8M
49.7M
46.97% -25.95%
-5.03
6.01
28.95% 32.80%
94.1M
2.6B
-43.99% -88.43%
-0.03
0.04
-13.88% -4855.92%

Financials for Ocular Therapeutix

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.4%49,72649,91449,36643,52238,562
  S&GA Expenses1.6%38,52537,91536,16635,19032,864
  R&D Expenses1.9%52,49751,49752,25650,08345,129
Interest Expenses2.1%6,8566,7176,6766,6716,718
Net Income-82.6%-59,346.00-32,501.00-22,216.00-6,553.00-88,315.00
Net Income Margin-83.3%-1.19*-0.65*-0.45*-0.15*-
Free Cahsflow-1.2%-59,994.00-59,289.00-68,103.00-66,744.00-
* denotes actual numbers (not divided by Thousands)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-8.4%159173188205218
  Current Assets-9.2%146160175191204
    Cash Equivalents-10.1%121135145164179
  Inventory3.0%22111
  Net PPE7.7%77777
Liabilities4.7%112107108117130
  Current Liabilities12.1%2926242625
Shareholder's Equity-29.7%4666808887
  Retained Earnings-4.2%-601.30-577.11-558.35-545.80-541.95
  Additional Paid-In Capital0.7%648643638634629
Accumulated Depreciation-15----
Shares Outstanding0.1%7777777777
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-0.3%-57,798.00-57,611.00-66,791.00-65,550.00-56,643.00
  Share Based Compensation3.0%16,57116,08916,10014,97713,240
Cashflow From Investing-30.9%-2,196.00-1,678.00-1,312.00-1,194.00-816.00
Cashflow From Financing-15.5%1,6631,9684,1422,851166,097

Risks for OCUL

What is the probability of a big loss on OCUL?

98.8%


Probability that Ocular Therapeutix stock will be more than 20% underwater in next one year

97.3%


Probability that Ocular Therapeutix stock will be more than 30% underwater in next one year.

72.3%


Probability that Ocular Therapeutix stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does OCUL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ocular Therapeutix was unfortunately bought at previous high price.

Drawdowns

Returns for OCUL

Cumulative Returns on OCUL

-6.3%


7-Year Cumulative Returns

-5.7%


5-Year Cumulative Returns

-4.2%


3-Year Cumulative Returns

What are the long-term rolling returns for OCUL?

FIve years rolling returns for Ocular Therapeutix.

Annualized Returns

Which funds bought or sold OCUL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-26
STRS OHIO
unchanged
-
-21,000
44,000
-%
2023-01-25
Hikari Power Ltd
unchanged
-
-23,000
48,000
-%
2023-01-25
DELTEC ASSET MANAGEMENT LLC
reduced
-20.26
-4,436,220
5,206,780
1.49%
2023-01-25
Lindbrook Capital, LLC
sold off
-100
-3,000
-
-%
2023-01-24
Centerpoint Advisors, LLC
unchanged
-
-4,000
10,000
-%
2023-01-19
Quent Capital, LLC
new
-
1,377
1,377
-%
2023-01-18
Verition Fund Management LLC
added
100
43,000
84,000
-%
2023-01-13
BEACON INVESTMENT ADVISORY SERVICES, INC.
unchanged
-
-16,280
33,720
-%
2023-01-09
Founders Capital Management
unchanged
-
-3,000
7,000
-%
2023-01-06
MASSMUTUAL TRUST CO FSB/ADV
added
75.41
-
-
-%

1–10 of 47

Latest Funds Activity

Are funds buying OCUL calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own OCUL
No. of Funds

Ocular Therapeutix News

Knox Daily

Buying Buzz: Ocular Therapeutix Inc. [OCUL] 10% Owner SUMMER ROAD LLC acquires 7,328 shares of the company.

Knox Daily,
14 hours ago

Marketing Sentinel

InvestorsObserver

Sector Update: Health Care.

InvestorsObserver,
21 days ago

Marketscreener.com

Benzinga

Schedule 13G FIlings of Ocular Therapeutix

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 03, 2022
blackrock inc.
6.7%
5,122,835
SC 13G/A
Feb 01, 2022
opaleye management inc.
7.80%
5,974,800
SC 13G/A
Feb 12, 2021
opaleye management inc.
8.65%
9
SC 13G/A
Feb 02, 2021
blackrock inc.
7.3%
5,512,264
SC 13G
Jun 09, 2020
blackrock inc.
4.8%
3,006,167
SC 13G/A
May 21, 2020
summer road llc
17.0%
11,387,656
SC 13D/A
Mar 25, 2020
summer road llc
18.9%
11,024,020
SC 13D/A
Feb 14, 2020
versant side fund iii, l.p.
0.1%
13,007
SC 13G/A
Feb 10, 2020
man group plc
1.58%
760,490
SC 13G/A
Feb 05, 2020
blackrock inc.
5.9%
2,829,644
SC 13G/A

OCUL Fair Value

Recent SEC filings of Ocular Therapeutix

View All Filings
Date Filed Form Type Document
Jan 06, 2023
8-K
Current Report
Nov 09, 2022
4
Insider Trading
Nov 07, 2022
8-K
Current Report
Nov 07, 2022
10-Q
Quarterly Report

Latest Insider Trading transactions for OCUL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-07
SUMMER ROAD LLC
bought
25,648
3.5
7,328
-
2022-10-11
SUMMER ROAD LLC
bought
38,993
3.8993
10,000
-
2022-10-10
SUMMER ROAD LLC
bought
39,982
3.9982
10,000
-
2022-09-29
SUMMER ROAD LLC
bought
75,987.7
4.0419
18,800
-
2022-09-28
SUMMER ROAD LLC
bought
4,920
4.1
1,200
-
2022-09-27
SUMMER ROAD LLC
bought
608,322
4.6794
130,000
-
2022-07-01
Ozden Rabia Gurses
acquired
-
-
6,667
chief medical officer
2022-06-16
Warden Charles M
acquired
-
-
8,933
-
2022-06-16
Heier Jeffrey S.
acquired
-
-
8,933
-
2022-06-16
RAINES MERILEE
acquired
-
-
8,933
-

1–10 of 50

Antony Mattessich
230
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue, net$ 11,965$ 12,153$ 37,419$ 31,214
Costs and operating expenses:    
Cost, Product and Service [Extensible List]ProductProductProductProduct
Cost of product revenue$ 1,073$ 1,310$ 3,528$ 3,298
Research and development13,71912,71939,91937,505
Selling and marketing10,1869,57629,39026,054
General and administrative8,5318,07723,87524,345
Total costs and operating expenses33,50931,68296,71291,202
Loss from operations(21,544)(19,529)(59,293)(59,988)
Other income:    
Interest income285737527
Interest expense(1,797)(1,658)(5,175)(4,991)
Change in fair value of derivative liability(1,133)23,8378,59862,249
Other income (expense), net1 (1) 
Total other income, net(2,644)22,1863,79757,285
Net (loss) income$ (24,188)$ 2,657$ (55,496)$ (2,703)
Net (loss) income per share, basic$ (0.31)$ 0.03$ (0.72)$ (0.04)
Weighted average common shares outstanding, basic76,975,83976,552,06076,829,43476,317,563
Net (loss) income per share, diluted$ (0.31)$ (0.23)$ (0.73)$ (0.75)
Weighted average common shares outstanding, diluted76,975,83985,446,88682,598,66682,086,795
Product    
Revenue:    
Total revenue, net$ 11,913$ 12,153$ 36,555$ 31,214
Collaboration revenue    
Revenue:    
Total revenue, net$ 52 $ 864 

OCUL Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 120,950$ 164,164
Accounts receivable, net19,80221,135
Inventory1,5451,250
Prepaid expenses and other current assets3,3184,751
Total current assets145,615191,300
Property and equipment, net7,1966,956
Restricted cash1,7641,764
Operating lease assets4,0044,867
Total assets158,579204,887
Current liabilities:  
Accounts payable5,3084,592
Accrued expenses and other current liabilities21,61420,121
Deferred revenue603 
Operating lease liabilities1,7441,624
Total current liabilities29,26926,337
Other liabilities:  
Operating lease liabilities, net of current portion4,6105,924
Derivative liability11,59420,192
Deferred revenue, net of current portion13,53313,000
Notes payable, net of discount25,19225,000
2026 convertible notes, net28,15226,435
Total liabilities112,350116,888
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized and 77,010,385 and 76,731,940 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively88
Additional paid-in capital647,521633,795
Accumulated deficit(601,300)(545,804)
Total stockholders' equity46,22987,999
Total liabilities and stockholders' equity$ 158,579$ 204,887